7953 results about "Intestino-intestinal" patented technology

The invention discloses an intestinal flora and obesity personalized diagnosis method based on a graph attention network, and relates to the technical field of obesity diagnosis, and the method comprises the following steps: collecting gene data, building a graph structure-based model for the data to predict obesity risk and provide personalized health suggestions, each piece of microbiome data is expressed as a weighted undirected graph, a microbiome graph is constructed, the association strength between microbiome groups is calculated, and the microbiome data is expressed as a graph structure. According to the method, the graph structure model considering the relevance between the microbiome groups is constructed, the self-adaptive graph convolutional network and the heterogeneous graph attention network are utilized, multi-modal information interaction between the microbiome and clinical data is deeply mined, the processing capacity of high-dimensional and complex microbiome data is improved, and the multi-modal information interaction between the microbiome and clinical data is improved. The accurate prediction of obesity risks and the provision of personalized health suggestions are realized, the prediction accuracy and generalization ability of the model are significantly improved, and a more effective personalized obesity diagnosis effect is achieved.

The invention relates to the technical field of health management, in particular to a gastrointestinal health assessment and management method based on big data, and the method comprises the following steps: S1, health data collection: collecting multi-dimensional health data of a user; s2, data preprocessing: preprocessing the collected multi-dimensional health data; s3, regulating and analyzing intestinal microecology, namely classifying and analyzing intestinal flora based on the intestinal flora gene sequencing data of the user in combination with living habits and diet data, identifying the condition of flora imbalance, and dynamically regulating flora balance through personalized regulation suggestions; s4, gastrointestinal health state evaluation: comprehensively evaluating the gastrointestinal health state of the user; and S5, generating a personalized health management scheme: generating the personalized health management scheme. According to the invention, by monitoring the health feedback of the user in real time, the scheme can be dynamically adjusted, so that the intervention is more flexible and targeted.

The invention discloses bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application of the bifidobacterium animalis subsp. Lactis, and belongs to the field of microorganisms. According to the invention, a strain of bifidobacterium anaticum subsp. Lactis LIHUO 01 is screened out, the strain is preserved in the Guangdong Microbial Culture Collection Center on November 20, 2024, and the preservation number is GDMCC No: 65512. The invention also discloses a preparation method of the bifidobacterium anaticum subsp. Lactis strain, and the bifidobacterium anaticum subsp. Lactis strain has the advantages that the bifidobacterium anaticum subsp. Lactis strain can be used for preparing the bifidobacterium anaticum subsp. Lactis strain; the bifidobacterium animalis subsp. Lactis LIHUO 01 has good in-vitro probiotic characteristics, has the effects of relieving ulcerative colitis, improving constipation and regulating intestinal flora, and has a good application prospect in preparation of food or health care products or medicines for relieving ulcerative colitis or improving constipation or regulating intestinal flora.

The invention discloses a quintuple bacterium for conditioning and improving diarrhea, constipation and irritable bowel syndrome. The quintuple bacteria comprise lactobacillus reuteri HBM11-69, pediococcus pentosaceus MPL5, lactobacillus plantarum La-10, lactobacillus rhamnosus HBM11-35 and lactobacillus casei C7-2 bacteria, and the lactobacillus rhamnosus HBM11-35, the pediococcus pentosaceus MPL5, the lactobacillus plantarum La-10, the lactobacillus rhamnosus HBM11-35 and the lactobacillus The strain is found by a Lin Junjunch Teaching Team of South China Agricultural University. The probiotic composition disclosed by the invention is mutually matched and has a synergistic effect, and the intestinal flora structure balance can be effectively recovered by improving the small intestine propulsion rate, reducing the diarrhea frequency and the like. No matter in a viable or inactivated state, the traditional Chinese medicine composition has a relatively good improvement effect on gastrointestinal discomfort such as constipation and irritable bowel syndrome. The quintuplet compound probiotics are high in safety, do not cause adverse reactions such as electrolyte imbalance and can be used for preparing medicines or health foods or foods.

The invention relates to the technical field of biological pharmacy, and discloses a probiotic microcapsule with a function of improving intestinal microecology, which comprises the following components in percentage by weight: lactobacillus rhamnosus: each gram of formula contains 1010 CFU of lactobacillus rhamnosus; lactobacillus acidophilus: each gram of the formula contains 109 CFU; clostridium butyricum: each gram of the formula contains 108 CFU; 5%-8% of a nano sodium alginate-chitosan compound; 3%-5% of peptide nanoparticles; 2%-4% of a natural polymer intelligent response film; 3%-6% of arabinoxylan oligosaccharide; 4%-7% of resistant dextran; 2%-4% of lentinan; and 0.1%-0.3% of resveratrol. Through a double-layer or three-layer embedding technology of the nano sodium alginate-chitosan compound and the intelligent response polymer film, the tolerance of the probiotics in gastric acid and cholate environments is remarkably enhanced, and targeted release of the probiotics in small intestines and colon is ensured.

The invention relates to the technical field of image enhancement, in particular to a method for detecting an intestinal lesion area of a child based on machine vision. Carrying out threshold segmentation on the grayscale image to obtain a reference point; clustering the reference points and partitioning the grayscale image according to the shape of a cluster; acquiring edge points and a to-be-optimized area according to the gradient of the pixel points in the block area; obtaining a target point according to the gray difference characteristics of the pixel points and the edge points of the to-be-optimized region; obtaining an abnormal point according to the gray difference characteristics of the target point and other target points in the neighborhood and the gray difference characteristics of the neighborhood of the edge points; and obtaining a gray adjustment range value according to the gray difference characteristics of the neighborhoods of the abnormal points and the edge points in the to-be-optimized region. According to the method, a final gray value is obtained according to a gray adjustment range value and a gray discrete feature of an edge point neighborhood; histogram equalization is carried out according to the final gray value, an intestinal tract detection enhanced image is obtained, and the image enhancement accuracy is improved.

The invention discloses lactobacillus kefiranofaciens IMAU12319 and application thereof, belongs to the technical field of microorganisms, and particularly relates to lactobacillus kefiranofaciens IMAU12319 which is preserved in China General Microbiological Culture Collection Center (CGMCC) on July 8, 2024, the preservation address is No. 3, No.1 yard, West Beichen Road, Chaoyang District, Beijing, and the number is CGMCC No.31224. The lactobacillus kefiranofaciens IMAU12319 has the advantages that the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319, and the lactobacillus kefiranofaciens IMAU12319 can be used for preparing the lactobacillus kefiranofaciens IMAU12319; the invention also relates to an application of the lactobacillus kefiranofaciens IMAU12319 in preparation of a probiotic agent capable of resisting gastrointestinal digestion. The strain disclosed by the invention not only shows good gastrointestinal tract endurance capacity, but also shows relatively strong potential in the aspects of intestinal adhesion, oxidation resistance and bacteriostasis, and has a wide application prospect in leavening agent strains.

The invention relates to application of breast milk oligosaccharides to improvement of intestinal flora of mothers and infants, in particular to application of 2 '-fucosyllactose to preparation of food which is taken by a mother and contributes to regulation of intestinal flora of the mother and offspring thereof, and the mother is in a gestation period and / or a lactation period. The invention is provided through a large amount of research; when a mother supplements a certain amount of 2 '-fucosyllactose in a gestation period and / or a lactation period, the abundance of beneficial bacteria in intestinal tracts of the mother can be remarkably improved, the content of harmful bacteria is reduced, meanwhile, the abundance of beneficial bacteria in intestinal tracts of filial generations of the mother is remarkably improved, and the content of harmful bacteria is reduced; particularly, the abundance of some beneficial bacteria which cannot be directly eaten in the intestinal tracts of the mother and the offspring can be adjusted.

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention discloses a self-adaptive intestinal function adjusting system based on biological feedback, and relates to the technical field of intestinal function adjustment, the self-adaptive intestinal function adjusting system comprises a signal acquisition module, a data analysis module, an adjustment feedback module and a user interaction module; the signal acquisition module adopts a multi-sensor fusion algorithm and a multi-source sensor to acquire intestinal function state information; wherein the multi-source sensor comprises a pressure sensor, a peristaltic sensor and a nerve sensor. The intestinal function self-adaptive adjusting system based on biological feedback can comprehensively collect biological signals of intestinal tracts, including pressure, peristalsis, nervous system signals and chemical substance secretion signals; the multi-dimensional monitoring mode can reflect the real state of the intestinal function more accurately, the limitation of a single sensor is avoided, and a rich and accurate data basis is provided for subsequent analysis and adjustment.

The invention relates to the technical field of medical informatics, and discloses an intestinal flora associated disease risk prediction system based on multi-data set difference mutual identification, and the system comprises the steps: capturing the dynamic evolution characteristics of a network through constructing a species-genus-phylum three-level microbial interaction network, and employing a time sequence diagram convolution network; and designing a network disturbance experiment, introducing a network recovery force index to quantify the network recovery capability, constructing a network vulnerability map to identify key nodes and analyze a disturbance propagation path, and integrating stable and consistent network toughness characteristics in multiple data sets to establish an early warning mechanism. By means of the method, early and accurate early warning of disease risks is achieved, and a key time window is provided for clinical intervention.

The invention relates to lactobacillus rhamnosus CBBM005 and application thereof in products for balancing intestinal flora, improving immunity and improving oral cavity, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus CBBM005 is separated from human intestinal secretion, the lactobacillus rhamnosus CBBM005 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation time is March 20, 2025, and the preservation number is CGMCC NO.33904. The lactobacillus rhamnosus CBBM005 has the characteristics of balancing intestinal flora, improving immunity and improving oral cavity.

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The invention relates to the technical field of microorganisms, and discloses a multifunctional compound probiotic composition which comprises the following raw materials in percentage by mass: 40-50% of probiotics; 30%-40% of a microcapsule embedding material; prebiotics: 10%-25%; 1%-5% of auxiliary materials; the invention also provides a preparation process of the multifunctional compound probiotic composition. The preparation process comprises the following steps: S1, culturing the probiotics and detecting the activity; s2, a microencapsulation process: preparing a multi-layer microcapsule through a spray drying method and an emulsion crosslinking method, and embedding the probiotics; and S3, mixing the microcapsules with prebiotics and auxiliary materials to obtain the multifunctional compound probiotic composition. By adopting a composite probiotic compatibility technology and through the synergistic effect of different strains, the stability and functionality of intestinal microecology are enhanced, and the effects of improving the survival rate of probiotics in gastrointestinal tracts, promoting planting of beneficial bacteria and enhancing the immunoregulation ability are achieved.

The invention provides lactobacillus plantarum NSL0125 and application thereof in preparation of a microbial preparation for promoting calcium supplement and growth and development. The lactobacillus plantarum NSL0125 is classified and named as Lactobacillus plantarum and is preserved in the China Center for Type Culture Collection, and the preservation number of the lactobacillus plantarum NSL0125 is CCTCC (China Center for Type Culture Collection) NO: M 2024609. The lactobacillus plantarum NSL0125 is high in safety, free of pathogenicity and capable of fermenting various nutrient substances to supply energy for growth. Experiments prove that the lactobacillus plantarum NSL0125 can be colonized in intestinal tracts for a long time, and meanwhile, the lactobacillus plantarum NSL0125 has unique effects on the aspects of adsorption, transfer, absorption promotion and the like of calcium ions, so that calcium absorption, growth and development of organisms are effectively promoted. The lactobacillus plantarum NSL0125 is high in fermentation level and suitable for large-scale industrial production. A large number of experimental studies prove that the lactobacillus plantarum NSL0125 and the microbial preparation thereof have remarkable effects of promoting calcium supplement and growth and development, have good application value and have good market application prospects.

The invention discloses a livestock intestinal parasitic disease diagnosis and treatment method based on a visual language large model, which comprises the following steps of: training the visual language large model by utilizing a parasite image-text feature alignment data set, so that the large language model has visual capability on parasites; then, constructing a livestock and poultry parasitic disease diagnosis and treatment dialogue data set, and training the LoRA fine-tuning visual language large model by using the diagnosis and treatment dialogue data set to obtain a diagnosis and treatment dialogue model; utilizing the diagnosis and treatment dialogue model to realize livestock parasitic disease diagnosis and treatment. The diagnosis and treatment efficiency of parasitic diseases of livestock and poultry can be improved, the misdiagnosis rate is reduced, and the diagnosis and treatment process is optimized.

The invention discloses bifidobacterium breve BBr69 with an immunoregulation function as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve BBr69 with the immunoregulation function is CGMCC (China General Microbiological Culture Collection Center) NO. 32425. Based on the strain, the invention also provides application and related products of the strain. The BBr69 strain has broad-spectrum antibacterial performance, has the function of regulating intestinal flora and also has the function of enhancing immunity, and immunity is enhanced by proliferating RAW264.7 cells, increasing the content of cell factors, inhibiting weight loss, increasing the index of immune organs and reducing ileum tissue damage.

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The invention provides infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the infant formula milk powder. The invention provides infant formula milk powder for the first time, the infant formula milk powder comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The infant formula milk powder can improve intestinal inflammation and / or microbial disorder.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention discloses bifidobacterium animalis subsp. Lactis BLa79 as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC (China General Microbiological Culture Collection Center) NO. 32426, and the preservation number of the bifidobacterium animalis subsp. Lactis BLa79 is CGMCC NO. 32426. Based on the strain, the invention also provides application and related products of the strain. The BLa79 strain has broad-spectrum antibacterial performance, has the function of regulating intestinal flora, can effectively relieve ulcerative colitis, and can relieve colitis by increasing body weight, reducing DAI score, reducing spleen index, inhibiting colonic atrophy, reducing proinflammatory factor level and promoting SIgA secretion.

Systems and methods for monitoring a bypass device for protecting an intestinal anastomosis are provided. The system includes a pump, one or more fluid inlet lines fluidicly coupled to the pump and to a negative pressure chamber of the bypass device, and one or more sensors configured to measure data indicative of pressure within the negative pressure chamber. A controller operatively coupled to the pump and the one or more sensors may be programmed to actuate the pump to generate a vacuum within the negative pressure chamber to thereby pull intestinal tissue towards the bypass device to anchor the bypass device at a target location upstream of the intestinal anastomosis. The controller further may compare the pressure within the negative pressure chamber with a predetermined pressure range and, if the pressure falls outside the predetermined pressure range, adjust the pump to maintain the vacuum within the predetermined pressure range.

The invention discloses application of astaxanthin as a feed additive in improving the disease resistance of macrobrachium rosenbergii, and belongs to the field of feed additives. According to the method, astaxanthin is supplemented in the feed, the survival rate of the juvenile macrobrachium rosenbergii after being infected with DIV1 is increased, meanwhile, the abundance of pathogenic bacteria in intestinal tracts after the macrobrachium rosenbergii is infected with DIV1 is reduced, then the purpose of preventing disease outbreak of the macrobrachium rosenbergii caused by DIV1 can be achieved, and the method is a sustainable and effective method for preventing and treating the macrobrachium rosenbergii DIV1 disease.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention provides a Kitasatospora xanthophycea JY01 strain and application thereof, the strain is separated from intestinal tracts of spring silkworms, has good disease-resistant and growth-promoting effects, and is specifically expressed in that cellulase, beta-1, 3-glucanase, siderophore and auxin IAA can be secreted; pot experiments show that the biocontrol efficiency of the microbial inoculum to wheat stalk rot is 57.90%, the biocontrol efficiency of the microbial inoculum to corn stalk rot is 46.41%, and the plant height and fresh weight are both significantly increased. The microbial agent is expected to be applied to preparation of biological bacterial fertilizer for effectively preventing and controlling soil-borne fungal diseases.

The invention relates to the technical field of microorganisms, in particular to application of lactobacillus rhamnosus KF7 in improving intestinal barrier injury and regulating intestinal flora and functional food containing the lactobacillus rhamnosus KF7. The invention provides application of lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The preservation number of the lactobacillus rhamnosus KF7 is CGMCC (China General Microbiological Culture Collection Center) NO.6430. The invention further provides application of the lactobacillus rhamnosus KF7 in preparation of a product for improving intestinal barrier injury and / or regulating intestinal flora. The invention discloses the novel application of the caseus rhamnosus KF7 in the aspects of improving the normal intestinal epithelial barrier function, protecting the normal intestinal epithelial barrier from lipopolysaccharide induced barrier injury, recovering animal intestinal barrier injury caused by rhythm disorder, regulating intestinal flora disorder and improving growth, development and metabolic states for the first time. The method can be used for producing functional food products such as fermented milk, lactic acid bacteria beverages, probiotic powder, viable bacteria water, milk powder and cheese.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum 9A-2 and application thereof in preparation of products for regulating intestinal tracts and protecting eyes. A probiotic product is successfully researched and developed on the basis of the lactobacillus plantarum, and verification shows that the lactobacillus plantarum can continuously provide endophytic essential isorhamnetin, chromium and vitamin H in the intestinal reproduction and growth process while regulating intestinal flora balance and promoting digestion, and also has the effect of relieving visual fatigue; particularly, visual fatigue caused by eye related diseases is relieved. The endophytic essential quantity of isorhamnetin, chromium and vitamin H can be continuously provided in the intestinal reproduction and growth process by feeding 3 billion strains and 200 milligrams of metabolites of the strain every day, visual fatigue caused by eye related diseases can be prevented and relieved, and the body health can be kept.

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The invention relates to application of fecal microbe transplantation (FMT) in depressive disorder treatment, in particular to application of a fecal microbe transplantation (FMT) composition based on a human intestinal tract fecal microbe composition in depressive disorder treatment. The invention also relates to application of the pharmaceutical composition or the medicine box in preparation of a medicine for treating depressive disorder, and the pharmaceutical composition or the medicine box contains a therapeutically effective amount of the human intestinal tract coprophilous fungus composition.

The invention discloses a vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions and a preparation method and application thereof, the vitamin K2 composite micro-capsule system with stomach protection and intestine slow release functions comprises three layers, namely a core layer, a middle layer and an outer layer from inside to outside in sequence; the core layer is formed by coating vitamin K2 with a zein-lac hydrophobic core, the middle layer is a pea protein-pectin electrostatic compound, and the outer layer is sodium alginate and chitosan double-network gel. The micro-capsule system provided by the invention can be tightly combined in a gastric acid environment after being orally taken, the release of active ingredients in the stomach is reduced, and then the micro-capsule system stays at intestinal mucosa for a long time and slowly releases contents, so that the functions of the micro-capsule system are slowly presented outside, the half-life period is prolonged, and the action effect is improved. Vitamin K2 directly or indirectly participates in and regulates various physiological processes related to health, and plays an important role in the aspects of maintaining bone health, preventing cardiovascular diseases, protecting nerves, improving metabolism and the like.